LENZ Therapeutics, Inc.

US$3.50As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:LENZHealthcare
Country USA
PE (Fwd) •••
TSR 3Y CAGR (50.88%)
Div yield —
ROE (72.69%)
Biotechnology
Beta (5Y) 1.81
PE TTM —
TSR TTM (88.22%)
Mkt cap US$110.0M
ROIC (48.31%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$4.01
14.58%
(64.87%)
Hold 12|12|3|7|10
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.04
0.04
0.04
0.05
1.70%
(5.28%)
1.29%
7.50%
Revenue$M
8.869
9.128
9.258
9.260
6.00%
9.81%
9.50%
6.25%
Peers (US$110.0M)
Cap (US$)
PE
110.0M
—
Capital
TTM
5Y
10Y
Leveragex
1.309
—
—
EBIT/Intx
3.179
0.780
0.838
Own earn%
(100.06)
51.08
37.23
Sh yield%
40.98
34.84
36.03
Owners
Insiders/Inst%
11.45
60.62
Short interest%
1.83
SBC / revenue%
5.61
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
19
Op margin range%
7–10
$1 testx
—
Incr. ROIC%
−3